Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Sulfur-containing biomolecules represent a broad category of organic compounds essential for life, including sulfur-containing amino acids like cysteine and methionine, the tripeptide glutathione, and gaseous signaling molecules such as hydrogen sulfide (H2S). These molecules are fundamental to cellular processes, particularly in maintaining redox homeostasis, facilitating protein folding via disulfide bond formation, and serving as methyl donors in epigenetic regulation [1][2]. In disease states, imbalances in sulfur metabolism are linked to oxidative stress, neurodegenerative disorders, and cancer progression [3]. While specific members of this class, such as glutathione, are frequently modulated by therapeutic agents like N-acetylcysteine to restore antioxidant capacity, the category as a whole is too broad to be classified as a single therapeutic target [4]. Consequently, drug development typically focuses on specific enzymes within sulfur metabolic pathways or individual sulfur-containing metabolites rather than the entire class [5]. This group of molecules is characterized by the presence of sulfur atoms, which allow for unique chemical reactivity, including the ability to undergo reversible redox reactions and form coordination complexes with metals [1]. Therapeutic intervention often involves the use of thiol-based drugs to protect against toxicity or to replenish depleted intracellular sulfur pools [4][5].
Drugs interacting with this class typically function by acting as precursors to essential thiols, directly scavenging reactive oxygen species, or serving as sulfur donors to modulate signaling pathways [4][5]. For instance, N-acetylcysteine provides a source of cysteine for glutathione synthesis, thereby enhancing the cell's antioxidant capacity [4]. Other agents, like Mesna, provide free thiol groups in the urinary tract to neutralize toxic metabolites of chemotherapy drugs [5].
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Sulfur-containing biomolecules.